Abstract
Higher prevalence of neuropathy has been described in patients with Parkinson’s disease (PD) in comparison with age and gender-matched controls. The cause of neuropathy may be levodopa-induced impairment of vitamin B12 metabolism, suggesting levodopa-naïve subjects should be unaffected. There may, however, be other yet unidentified determinants of neuropathy in PD. We screened 33 consecutive levodopa-naïve PD patients for neuropathy. Demographics, vitamin B12 and folate levels were studied. Findings were analyzed in the light of our previous available data on levodopa-treated PD patients. Four of 33 (12.1 %) levodopa-naïve PD patients were diagnosed with neuropathy. This compared to 13/36 (36.1 %) previously evaluated levodopa-treated patients (p = 0.027) and 3/37 controls (p = 0.7). Analysis of our whole PD cohort consisting of a total of 70 subjects, including levodopa-naïve and levodopa-treated patients, revealed that neuropathy correlated with use of levodopa (p = 0.041), cumulative levodopa exposure (p = 0.046), age at time of study (p = 0.005) and serum folate levels <10 μg/L (p = 0.003). There was no association of neuropathy with PD duration. Multivariate regression analysis showed that neuropathy was only independently associated with age (p = 0.016) and serum folate levels <10 μg/L (p = 0.012). We conclude that this study confirms the roles of levodopa usage and cumulative levodopa exposure in the neuropathy of PD. However, the effects of levodopa only appear contributory and are surpassed by age and lower folate levels. In view of the independent implication of lower folate levels, the need for preventative/protective supplementation including folate in addition to vitamin B12, probably irrespective of levodopa use, may deserve consideration in patients with PD.
Similar content being viewed by others
References
Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D (2008) Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord 23:1850–1859
Toth C, Breithaupt K, Ge S et al (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson’s disease. Ann Neurol 67:28–36
Rajabally YA, Martey J (2011) Neuropathy in Parkinson disease. Prevalence and determinants. Neurology 77:1947–1950
Singleton JR, Bixby B, Russell JW et al (2008) The Utah early neuropathy scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst 13:218–227
England JD, Gronseth GS, Franklin G, American Academy of Neurology et al (2009) Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American academy of neurology, American association of neuromuscular and electrodiagnostic medicine, and American academy of physical medicine and rehabilitation. Neurology 72:185–192
Rampersaud G, Kauwell GP, Bailey LB (2003) Folate: a key to optimizing health and reducing disease risk in the elderly. J Am Coll Nutr 22:1–8
Clarke P, Sherliker P, Hin H et al (2008) Folate and vitamin B12 status in relation to cognitive impairment and anaemia in the setting of voluntary fortification in the UK. Br J Nutr 100:1054–1059
Rösche J, Uhlmann C, Fröscher W (2003) Low serum folate levels as a risk factor for depressive mood in patients with chronic epilepsy. J Neuropsychiatry Clin Neurosci 15:64–66
Morris MS, Jacques PF, Rosenberg IH, Selhub J (2007) Folate and vitamin B12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 85:193–200
Taskforce of the Movement Disorder Society (2002) Management of Parkinson’s disease: an evidence-based review. Levodopa. Mov Disord 17(S4):S23–S37
Wahlin A, Bäckman L, Hultdin J, Adolfsson R, Nilsson LG (2002) Reference values of serum vitamin B12 and folic acid in a population-based sample of adults between 35 and 80 years of age. Public Health Nutr 5:505–511
Manzoor M, Runcie J (1976) Folate-responsive neuropathy: report of 10 cases. Br Med J 1:1176–1178
Botez MI, Peyronnard JM, Bachevalier J, Charron L (1978) Polyneuropathy and folate deficiency. Arch Neurol 35:581–584
Parry TE (1994) Folate responsive neuropathy. Presse Med 23:131–137
Koike H, Takahashi M, Ohyama K, Hashimoto R, Kawagashira Y, Iijima M, Sobue G (2013) The significance of folate deficiency in peripheral neuropathy. Abstract meeting of the peripheral nerve society. J Peripher Nerv Syst 18S2:57
Müller T, Renger K, Kuhn W (2004) Levodopa-associated increase in homocysteine levels and sural axonal degeneration. Arch Neurol 61:657–660
Ceravolo R, Cossu G, Bandettini di Poggio M et al (2013) Neuropathy and Levodopa in Parkinson’s disease: evidence from a multicentre study. Mov Disord [E-Pub ahead of print]
Montastruc JL, Danton AC, Durrieu G, French Association of Regional Pharmocovigilance Centres et al (2010) Neuropathy as a potential complication of levodopa use in Parkinson’s disease: a pharmacological and pharmacovigilance point of view. Mov Disord 25:660–661
Acknowledgments
The authors thank Dr. Richard J. Abbott, Department of Neurology, University Hospitals of Leicester, Leicester, U.K. for his help, support and advice in relation to this work.
Conflicts of interest
Y.A. Rajabally has received speaker/consultancy honoraria from LfB France, Griffols and BPL. Y.A. Rajabally has received educational sponsorships from LfB France, CSL Behring and Baxter. J. Martey received an educational grant from GSK and honoraria from Abbott Laboratories and UCB.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rajabally, Y.A., Martey, J. Levodopa, vitamins, ageing and the neuropathy of Parkinson’s disease. J Neurol 260, 2844–2848 (2013). https://doi.org/10.1007/s00415-013-7079-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-013-7079-8